Fact CheckerSign in

NCT07533851CompletedPhase 1

A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.

Source: ClinicalTrials.gov · Last updated 8 Jun 2026

Brief summary (registry, in English)

This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect of VC005 Tablets in healthy subjects

Status (registry)
Completed
Phase (registry)
Phase 1
Study type
Interventional
Enrollment
31 (actual)
First submitted
10 Apr 2026
Start date
23 Apr 2026
Primary completion date
30 Apr 2026
Lead sponsor
Jiangsu vcare pharmaceutical technology co., LTD
NCT number
NCT07533851

What you commit to

  • Study type: Interventional · Phase 1
  • Participants enrolled: 31
  • From 23 Apr 2026 to the primary completion date, 30 Apr 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • More than 5 cigarettes per day on average within 3 months prior to screening;
  • Donation or loss of a significant volume of blood (\> 400 mL) within 3 months prior to screening;
  • Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to receiving study drug;

Other illness

  • History of sensitivity to drugs similar to the study drug;allergic constitution (e.g. allergy to two or more kinds of drugs and food );
  • History of drug and/or alcohol abuse (alcoholism defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or or have used drugs within the past five years;
  • History of difficulties in swallowing or any history of gastrointestinal, liver, kidney disease (whether cured or not) or surgery that affects drug absorption or excretion;

Who the study is looking for

  • Able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions;
  • Able to complete the study in compliance with the protocol;
  • Subject (including partner) is willing to voluntarily take effective contraceptive measures from screening through 3 months after the last dose of study drug ;
  • Male and female subjects between the ages of 18 and 45 years, inclusive;
  • At least 50.0kg for male subjects, 45.0kg for female subjects, with a Body Mass Index (BMI= Weight/Height2) between 19.0-26.0 kg/m2, inclusive;

Age in the registry: 18 years to 45 years · Sex: All · Accepts healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Zhongda Hospital,Affiliated to Southeast
Coordinator of this site? Confirm its status
NanjingChinaUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.